Do Molecular Structures of Migraine Drugs Point to a Common Cause of this Elusive Disease and Suggest Future Drug Designs?
Abstract
We should, perhaps, consider migraine as a two-stage disorder. Stage 1 is the underlying biochemical disorder (migraine disorder) that predisposes the sufferer to stage 2, which is the manifestation of the disorder as a migraine headache.
Read the paper
Related studies
- Meta-analysis of genome-wide association for migraine in six population-based European cohorts
- New and sex-specific migraine susceptibility loci identified from a multiethnic genome-wide meta-analysis
- microRNA profiling in atherosclerosis, diabetes, and migraine
- Genome‐Wide‐Associated Variants in Migraine Susceptibility: A Replication Study From North I ndia
- Pharmacoinformatics elucidation of potential drug targets against migraine to target ion channel protein KCNK18
- Upregulation of IL-1 Receptor Antagonist in a Mouse Model of Migraine
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.